NDA 022514 · Boehringer Ingelheim
Mirapex Er
Pramipexole Dihydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Mar 19, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Mar 19, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
127
41 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 19, 2010 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval LabelReviewOther Important Information from FDA
5 products under this application
- MIRAPEX ER · PRAMIPEXOLE DIHYDROCHLORIDE 3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- MIRAPEX ER · PRAMIPEXOLE DIHYDROCHLORIDE 0.75MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- MIRAPEX ER · PRAMIPEXOLE DIHYDROCHLORIDE 4.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- MIRAPEX ER · PRAMIPEXOLE DIHYDROCHLORIDE 1.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- MIRAPEX ER · PRAMIPEXOLE DIHYDROCHLORIDE 0.375MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pramipexole Dihydrochloride" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.Pivotal-lookingTerminated
Areteia TherapeuticsIndustry
NCT05763121 · 1,061 participants · Start Jan 30, 2023 · Primary completion Dec 8, 2025
Drug: Dexpramipexole Dihydrochloride; Placebo · For: Eosinophilic Asthma; Asthma; Eosinophilic; Asthma
Sites: Bakersfield, California; La Palma, California; Newport Beach, California · 401 sites in all
- Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome PatientsPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00806026 · 731 participants · Start Dec 2008 · Primary completion May 2011
Drug: placebo and pregabalin; pramipexol and 4 more · For: Idiopathic Restless Legs Syndrome
Sites: Birmingham, Alabama; Jasper, Alabama; Tuscaloosa, Alabama · 110 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT02233023 · 705 participants · Start Jun 1998 · Primary completion Jun 2000
Drug: Pramipexole; Bromocriptine and other dopamine agonists · For: Parkinson Disease
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT00605683 · 679 participants · Start Nov 2007 · Primary completion Jan 2012
Drug: Safinamide (as add-on therapy); Safinamide (as add-on therapy) and 1 more · For: Idiopathic Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Oxnard, California · 125 sites in all
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)Pivotal-lookingTerminated
Areteia TherapeuticsIndustry
NCT05813288 · 654 participants · Start Mar 27, 2023 · Primary completion Dec 8, 2025
Drug: Dexpramipexole Dihydrochloride; Placebo · For: Eosinophilic Asthma; Asthma; Eosinophilic; Asthma
Sites: Mobile, Alabama; Chandler, Arizona; Peoria, Arizona · 282 sites in all
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaPivotal-lookingActive, not recruiting
Areteia TherapeuticsIndustry
NCT05748600 · 600 participants (planned) · Start Jan 30, 2023 · Primary completion Sep 2025
Drug: Dexpramipexole Dihydrochloride; Placebo · For: Eosinophilic Asthma; Asthma; Eosinophilic; Asthma Attack
Sites: Chandler, Arizona; Peoria, Arizona; Surprise, Arizona · 335 sites in all
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sPivotal-lookingCompleted
Pharma Two B Ltd.Industry
NCT03329508 · 544 participants · Start Jan 19, 2018 · Primary completion Aug 23, 2021
Drug: P2B001 0.6/0.75 mg; Rasagiline 0.75 mg and 2 more · For: Parkinson Disease; Early Parkinson's Disease
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mirapex ER (Pramipexole Di-HCl)
2024 spending
$54K
Beneficiaries
23
45 claims
Per beneficiary
$2,331
$23.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,825,737 |
| 2021 | $1,533,817 |
| 2022 | $1,288,060 |
| 2023 | $794,263 |
| 2024 | $53,612 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pathological gambling caused by drugs used to treat Parkinson disease.
Dodd ML, Klos KJ, Bower JH, et al. · Arch Neurol 2005 · Clinical Trial, Comparative Study
- Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.
Brodsky MA, Park BS, Nutt JG · Arch Neurol 2010 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period Crossover Clinical Trial.
Yang L, Zhang L, Luo Z · Drug Des Devel Ther 2023 · Clinical Trial, Phase I, Comparative Study
- Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
· Arch Neurol 2009 · Comparative Study, Multicenter Study
- Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
Hauser RA, McDermott MP, Messing S · Arch Neurol 2006 · Randomized Controlled Trial
- Comparative pharmacokinetics for bioequivalence of pramipexole dihydrochloride extended-release tablets in fasting and fed Chinese healthy volunteers: a randomized, open-label, single-dose, crossover study.
Chen Q, Shi HQ, Chen YF, et al. · BMC Pharmacol Toxicol 2026 · Randomized Controlled Trial, Comparative Study
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.